Incidence increasing along with number of patients who are overweight or obese.
Associated with increased cardiovascular risk.
May cause acute pancreatitis when fasting levels >5.7 mmol/L (500 mg/dL).
Treatment includes lifestyle modification for all patients.
Statins are generally first-line pharmacotherapy in patients with triglycerides <5.69 mmol/L (<500 mg/dL) in the presence of ≥2 cardiac risk factors.
Fibric acid derivatives, fish oils, and/or nicotinic acid may be added to statins, to achieve targets, in patients with triglycerides <5.69 mmol/L (<500 mg/dL), or as first-line therapy in those with triglycerides ≥5.69 mmol/L (≥500 mg/dL).
Hypertriglyceridaemia is defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) as fasting plasma triglyceride level ≥2.3 mmol/L (≥200 mg/dL). Borderline high is defined as 150 to 199 mg/dL, high as 200 to 499 mg/dL, and very high as ≥500 mg/dL.  Chylomicronaemia is present when triglyceride level is ≥11.3 mmol/L (≥1000 mg/dL).
Professor of Medicine
VA Greater Los Angeles Healthcare System and UCLA School of Medicine
DAL is an author of several references cited in this monograph.
Use of this content is subject to our disclaimer